

## PRESS RELEASE

31 MARCH 2026

---

### NUMBER OF SHARES AND VOTES IN NANOLOGICA AB (PUBL)

**The number of registered shares and votes in Nanologica AB has changed during the month of March as a result of the directed share issues resolved by the board of directors on 30 January 2026 and approved at the subsequent extraordinary general meeting on 4 March 2026 (the "Directed Issues").**

The Directed Issues comprised a total of 34,203,780 shares, of which 31,603,780 shares have been partially registered during the month of March. The remaining 2,600,000 shares are expected to be registered in connection with the company's rights issue. This means that the number of shares in Nanologica during March has increased by 31,603,780 shares from 88,369,820 to 119,973,600 shares and that the share capital has increased by SEK 1,611,792.78 from SEK 4,506,860.82 to SEK 6,118,653.60.

As of 31 March 2026, the last trading day of the month, the total number of shares and votes in Nanologica AB amounted to 119,973,600.

**For further information, please contact:**

Johanna Westerberg, Director IR, Communications and Marketing  
Ph: +46 72 211 21 90 or e-mail: [ir@nanologica.com](mailto:ir@nanologica.com)

*This information is information that Nanologica AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act (1991:980). The information was submitted for publication, through the agency of the contact person set out above, on 31 March 2026, 09:15 CEST.*

---

#### **About Nanologica AB (publ)**

Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica's products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The Group also includes Syntagon, a contract manufacturer of drug molecules for both clinical studies and commercial delivery. Syntagon works with chemical engineering manufacturing and the development of processes and analyses of pharmaceutical raw materials, with a core competence in small molecules and peptides, and a particular strength in purification and analysis of complex compounds. The Group is headquartered in Södertälje and Nanologica's share (NICA) is listed for trading on Nasdaq Stockholm Main Market. For further information, please visit [www.nanologica.com](http://www.nanologica.com).